SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

LUNRs sharp rebound is being linked to NASAs CLPS 2 lunar-services awards, with traders pointing to claims of a company selection while others question whether the news is confirmed or priced in. The move has intensified debate over short covering and whether the rally can hold ahead of earnings.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Interim ARO-MAPT results showing a substantial reduction in spinal-fluid tau in healthy volunteers have focused attention on Arrowheads potential subcutaneous RNAi delivery to the brain. Many traders view the data as a validation of the platform, while others note that clinical benefit in patients remains unproven and are frustrated by the stocks muted reaction.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

ETs latest earnings update is drawing attention: traders note an earnings miss alongside higher full-year EBITDA guidance, with some viewing the stronger outlook as supportive and others questioning the muted performance. The pullback is also being attributed to higher interest rates and borrowing costs, while investors debate whether data-center gas demand can drive further growth.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO is drawing attention as traders use the leveraged inverse crude ETF to bet on oils direction amid shifting Iran and Strait of Hormuz conflict and peace-deal expectations. Some expect de-escalation and lower oil prices to lift SCO, while others complain that futures exposure, backwardation and daily-reset decay have caused it to lag crudes moves.

Victoria's Secret & Co. operates as a lingerie, clothing and beauty retailer. It offers bras, panties, lingerie, sleepwear, apparel, sport and swim apparel, and beauty products. The company was founded in 1963 and is headquartered in Reynoldsburg, OH.

Victoria`s Secret & Co

Victorias Secrets strong quarterly results and raised full-year outlook, attributed to improving demand and its turnaround strategy, have fueled a sharp rally and talk of short covering. Bulls see renewed brand momentum, while bears argue the surge has outpaced the companys fundamentals and may be unsustainable.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Debate over Johnson & Johnsons bleximenib AML data is driving attention, with traders weighing whether it threatens Kuras ziftomenib in frontline treatment and questioning how comparable the patient groups are. Some view the competitive news as an overreaction, pointing to KOMZIFTIs launch progress and upcoming clinical updates; others see a meaningful competitive risk.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares are under pressure despite an earnings beat and higher outlook, as traders focus on planned workforce cuts and restructuring tied to AI, alongside a slight revenue miss and unchanged adjusted earnings guidance. Bulls view the selloff as an overreaction, pointing to resilient card spending and credit quality.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,505.961324. The last known price of Zebec Network is 0.00185282 USD and is down -2.31 over the last 24 hours. It is currently trading on 133 active market(s) with $11,016,611.66 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Zebecs payroll and payments partnershipsespecially the MoneyGram/Stellar integration and reported Germany/AllUnity deploymentare fueling discussion, alongside unconfirmed speculation about Robinhood. Bulls see these developments as signs of growing adoption, while skeptics argue that partnerships have yet to translate into sustained ZBCN demand or stronger price performance.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons quarterly earnings beat, with unusually strong refining profits amid tight diesel supply and record U.S. refinery throughput, is driving attention. Traders are weighing the stronger cash flow and debt reduction against concerns that refining gains may be temporary, while some are also debating whether the recent rally has run too far.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,098,130.40630647. The last known price of Pepe is 0.00000498 USD and is up 2.29 over the last 24 hours. It is currently trading on 729 active market(s) with $440,504,313.03 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPEs sharp swings and repeated struggles to hold above a key round-number level dominate the discussion, with traders watching technical support and resistance. Some see recent rebounds as a potential breakout and are buying dips, while others view them as temporary bounces amid broader crypto-market weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC...

Citigroup Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00

Citigroup lowered their price objective on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a 'buy' rating on the stock in a research report on Tuesday...

Oric Pharmaceuticals (NASDAQ:ORIC) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.03...

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned...

Oric Pharmaceuticals (ORIC) to Release Earnings on Monday

Oric Pharmaceuticals (NASDAQ:ORIC) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-oric-pharmaceuticals-inc-stock...

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofORIC Pharmaceuticals, Inc. (Oricor the Company) (NASDAQ:ORIC) for violations of the securities laws.The investigation focuses on whether the Company issued false...

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5% - Still a Buy?

Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 6.5% - Here's Why...

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the company...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Jones Research maintained a ‘Buy’ rating on the stock with a $25 price target, according to The Fly.</li><li>Wedbush Securities lowered its price target to $17 from $20 but maintained an ‘Outperform’ rating.</li><li>Cantor Fitzgerald said Rinzimetostat’s efficacy appears comparable to competitor Mevrometostat from Pfizer</li></ul>Shares of Oric Pharmaceuticals (ORIC) plunged 28% on Wednesday as investors reacted to tolerability concerns tied to a higher dose of its prostate cancer drug, even as analysts said the sharp sell-off appears exaggerated.<a href="https://stocktwits.com/symbol/ORIC">ORIC shares</a> recorded their biggest intraday slump in more than four years.<h2 class="st-heading-2">Oric Selects 400 MG Dose Of Rinzimetostat</h2>On Tuesday, Oric <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">announced</a> it selected a lower 400 mg dose of its investigational drug Rinzimetostat. In the Phase 1 trial involving patients with metastatic castration-resistant prostate cancer, the 600 mg dose showed a higher rate of side effects, dose interruptions, and discontinuations when combined with darolutamide.By contrast, the 400 mg dose demonstrated a more manageable safety profile, with mostly mild side effects and only limited severe (Grade 3) events. The company now plans to move forward with the lower dose in a global Phase 3 trial in the first half of 2026.<h2 class="st-heading-2">Analysts Say Selloff is Exaggerated</h2>Despite the sharp selloff, analysts suggest the reaction may be overdone. Jones Research noted that the data appears broadly in line with Pfizer’s competing drug Mevrometostat, while potentially offering a better safety profile, according to The Fly.The firm said the selloff ‘appears exaggerated,” pointing out that Oric’s data is still early, with only about five months of follow-up compared to nine to 10 months for Pfizer’s results. Jones &nbsp;Research maintained a ‘Buy’ rating on the stock with a $25 price target.Other firms, including Cantor Fitzgerald and Wedbush, highlighted that efficacy remains comparable. “Efficacy appears comparable to competitor Mevrometostat from Pfizer, with Rinzi showing a potentially better safety profile,” Cantor said. It has an ‘Overweight’ rating on Oric shares.<h2 class="st-heading-2">Wedbush Says Results broadly In Line With Pfizer’s Drug</h2>Meanwhile, David Nierengarten of Wedbush Securities lowered his price target to $17 from $20 while maintaining an ‘Outperform’ rating. The analyst said Oric’s Phase 1 prostate cancer results are broadly in line with Pfizer’s, even though Oric tested its drug in a sicker patient group.He added that while greater efficacy differences are ideal, better tolerability is important, especially for older patients on long-term treatment, and could influence doctors’ choices if both drugs are similarly effective.Despite the sharp selloff, retail sentiment turned ‘extremely bullish’ from ‘neutral’ a day earlier.One user said the stock has "really good upside potential"<stembedurl>https://stocktwits.com/LF5/message/649195078</stembedurl>The stock has gained more than 10% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Oric Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Oric shares tanked after the firm selected a lower 400 mg dose of its investigational drug for prostate cancer after its 600 mg dose showed a higher rate of side effects.

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says ‘Selloff Appears Exaggerated’

Pfizer Inc

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$8.82
Prev Close	$8.49
Open	$8.61
Dividend Yield	0.00%
50-Day Moving Average	$11.99
Beta	1.44
Avg. Volume	1.89M
PE Ratio	-6.53

52-Week High	$14.68
52-Week Low	$7.23
Market Capitalization	$914.22M
EPS (Annual)	-$1.47
Price to Book	2.40
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ORIC Fundamentals